MedTrace Logo

AT-301 Nasal Spray in Healthy Adults

NCT04519788 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-01-19

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study. The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part 1) followed by a multiple ascending dose (MAD) part (Part 2).

Conditions

  • Healthy

Interventions

DRUG

AT-301B

Nasal Spray

DRUG

AT-301A

Nasal Spray

Sponsors & Collaborators

  • Atossa Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Ben Canny · Bellberry Limited HREC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-07
Primary Completion
2020-12-08
Completion
2021-01-12
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04519788 on ClinicalTrials.gov